SOHO 2021

Parsaclisib Improved Myelofibrosis Symptoms in Patients With Suboptimal Response to Ruxolitinib

At 12 weeks, most patients had a reduction in spleen volume.

Updated Safety and Efficacy of CAR T-Cell Therapy Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma

A single dose of cilta-cel yielded early, deep, and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma.

How Prior Alkylator Exposure Impacts the Efficacy of Melflufen in Multiple Myeloma

Patients with fewer prior lines of therapy in which they were exposed or refractory to alkylators generally had better outcomes.

Gilteritinib Shows Efficacy in Patients With Acute Myeloid Leukemia With Prior Tyrosine Kinase Inhibitor Therapy

Researchers sought to determine whether gilteritinib would have efficacy in patients with relapsed/refractory AML who had received prior TKI therapy.

Tafasitamab Plus Lenalidomide May Improve Overall Survival in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Researchers sought to determine whether tafasitamab with lenalidomide would improve outcomes for patients with relapsed/refractory DLBCL.

Comorbidities Don’t Hinder Dasatinib’s Activity in Chronic Phase Chronic Myeloid Leukemia

Dasatinib produced responses regardless of comorbidity burden.

Brentuximab Vedotin Plus CHP Provides Lasting Benefit in Peripheral T-Cell Lymphoma

The combination continued to best CHOP at 5 years.

Upfront Daratumumab Shows Survival Benefit in Combination for Transplant-Ineligible Multiple Myeloma

Researchers sought to determine if there would be a survival benefit with daratumumab combined with lenalidomide and dexamethasone in patients with transplant-ineligible MM.

Algorithmic Approach to Identify Patients With Germline Predisposition Syndromes, Including Those With Hematologic Malignancies

Researchers sought to identify patients with germline predisposition syndromes without syndromic features using an algorithmic approach compared with classic methods.

Graft Vs Host Prophylaxis With Posttransplant Cyclophosphamide Not Associated With Increased Infection Risk

Researchers sought to determine whether GVHD prophylaxis with posttransplant cyclophosphamide following allo-HSCT would be associated with a higher risk of infection.

Posttransplant Cyclophosphamide Safety With Haploidentical Transplantation

Researchers sought to determine if treatment with PTCy is safe for patients with hematologic malignancies in the HLA-haploidentical setting.

Clinical and Molecular Features May Predict Indolent Chronic Myelomonocytic Leukemia

Mutations in JAK2, SF3B1, and IDH2 were associated with indolent disease.

Isatuximab Improves PFS in Elderly Patients with Relapsed Multiple Myeloma

Adding isatuximab to carfilzomib and dexamethasone also improved the depth of response.

CAR T-Cell Therapies Show Similar Efficacy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Survival outcomes were comparable for patients who received tisagenlecleucel and those who received lisocabtagene maraleucel.

Pirtobrutinib Demonstrates Favorable Efficacy in Patients With B-Cell Malignancies

Researchers sought to determine the recommended phase 2 dose, safety, and efficacy of pirtobrutinib in patients with B-cell malignancies.

Neuropsychiatric Disorders Common in Patients Who Receive CAR-T Therapy for Multiple Myeloma

Researchers sought to determine whether there was an association between NPDs and CAR-T therapy in patients with multiple myeloma.

Genetic Ancestry Impacts Treatment Outcomes in Acute Lymphoblastic Leukemia

Researchers found a “strong genetic basis” for racial differences in survival.

Nivolumab Plus Brentuximab Vedotin Deemed ‘Highly Active’ in Rel/Ref Primary Mediastinal Large B-Cell Lymphoma

The median duration of response was 31.6 months, and the median duration of complete response was not reached.

Venetoclax Combined With FLAG-IDA Yields High Response Rates in Patients With Newly Diagnosed Acute Myeloid Leukemia

Researchers sought to determine whether FLAG-IDA with venetoclax would yield MRD-negative composite complete remission in patients with newly diagnosed AML.

Real-World Data Confirm Poor Survival in Triple-Exposed Multiple Myeloma

After initial triple-class exposure, most patients received a combination of triple-class agents and other agents.